To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy - To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group0 个研究点目标入组 48 人开始时间: 2010年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Treatment with tegafur gimestat otastat potassium Within 7 days 2)History of the serious hypersensitivity for Fluorouracil , Levofolinate calcium,platinum or bevacizumab 3) Active multiple Primary cancer within 5 years 4) History of adverse events related to DPD loss 5) Uncontrolled diarrhea 6) Any surgical treatments oncluding skin-open biopsy,trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week 7)Complication of cerebrovascular disease or symptoms within 1 years 8) Administering antithrombotic drug within 10 days before enrollment 9)Need tobadministrate or having anti-plateles therapy(including Methotrexate aspirin and NSAIDS) 10)Evidence of bleeding diathesis or coagulopathy 11)Symptom of colorectal obstruction 12)uncontrolled complication of peptic ulcer 13)Current or previous (within the last 1 year) history of GI perforation 14)Renal failure to be treated,2+ or higher proteinuria within 2 weeks prior to entry 15)Uncontrolled Hypertension 16)Uncontrolled Infection 17)Pregnant women,possibly pregnant women,wishing to become pregnant,and nursing mothers 18)Man who doesn't practice birth control 19)Treatment history of Oxlplatin 20)Other conditions not suitable for this study

发起方

Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group